- Ustekinumab for the treatment of refractory pediatric Crohn’s disease: a single-center experience
-
Cohen A, Ahmed N, Sant’Anna A
- KMID: 2515480
- Intest Res.
- 2021 Apr;19(2):217-224.
- doi: 10.5217/ir.2019.09164
Background/Aims: Despite the well-established efficacy of tumor necrosis factor (TNF) antagonists as treatment options for Crohn’s disease, many pediatric patients need a change in therapy due to adverse events and... -
- CITED
-
- Close
- SHARE
-
- Close
